JP5894364B2 - 眼および付属器組織の炎症を処置するための治療組成物 - Google Patents

眼および付属器組織の炎症を処置するための治療組成物 Download PDF

Info

Publication number
JP5894364B2
JP5894364B2 JP2010521046A JP2010521046A JP5894364B2 JP 5894364 B2 JP5894364 B2 JP 5894364B2 JP 2010521046 A JP2010521046 A JP 2010521046A JP 2010521046 A JP2010521046 A JP 2010521046A JP 5894364 B2 JP5894364 B2 JP 5894364B2
Authority
JP
Japan
Prior art keywords
eye
composition
pharmaceutical composition
seq
blepharitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010521046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516400A (ja
JP2011516400A5 (enExample
Inventor
レーザ ダナ
レーザ ダナ
モハンマド ダスジャーディ
モハンマド ダスジャーディ
Original Assignee
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド, ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド filed Critical ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Publication of JP2011516400A publication Critical patent/JP2011516400A/ja
Publication of JP2011516400A5 publication Critical patent/JP2011516400A5/ja
Application granted granted Critical
Publication of JP5894364B2 publication Critical patent/JP5894364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2010521046A 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物 Active JP5894364B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96513507P 2007-08-16 2007-08-16
US60/965,135 2007-08-16
US13068708P 2008-06-02 2008-06-02
US61/130,687 2008-06-02
PCT/US2008/009776 WO2009025763A2 (en) 2007-08-16 2008-08-15 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015227544A Division JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Publications (3)

Publication Number Publication Date
JP2011516400A JP2011516400A (ja) 2011-05-26
JP2011516400A5 JP2011516400A5 (enExample) 2016-01-14
JP5894364B2 true JP5894364B2 (ja) 2016-03-30

Family

ID=40378866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521046A Active JP5894364B2 (ja) 2007-08-16 2008-08-15 眼および付属器組織の炎症を処置するための治療組成物
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015227544A Pending JP2016065089A (ja) 2007-08-16 2015-11-20 眼および付属器組織の炎症を処置するための治療組成物

Country Status (5)

Country Link
US (2) US10105441B2 (enExample)
EP (1) EP2187900B1 (enExample)
JP (2) JP5894364B2 (enExample)
AU (1) AU2008289552B2 (enExample)
WO (1) WO2009025763A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5894364B2 (ja) * 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
JP2012515164A (ja) * 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
US9707126B2 (en) 2009-10-21 2017-07-18 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP4480461A3 (en) 2010-03-19 2025-02-12 Avedro, Inc. Systems for applying and monitoring eye therapy
WO2012000904A1 (en) * 2010-06-28 2012-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical composition for use in the treatment of glaucoma
KR20130083900A (ko) * 2010-06-30 2013-07-23 존슨 앤드 존슨 비젼 케어, 인코포레이티드 케모카인 길항제를 함유하는 안과 장치
NZ605928A (en) 2010-07-29 2015-02-27 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US20140147413A1 (en) * 2011-02-28 2014-05-29 Dong Feng Chen Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
AU2012228769B2 (en) 2011-03-14 2016-09-08 Phlogo Aps Antagonists of the interleukin- 1 receptor
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9044308B2 (en) 2011-05-24 2015-06-02 Avedro, Inc. Systems and methods for reshaping an eye feature
US9020580B2 (en) 2011-06-02 2015-04-28 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
KR20140054002A (ko) * 2011-06-29 2014-05-08 인사이트 비젼 인코포레이티드 재발성 눈꺼풀판샘 장애를 치료하는 방법 및 이로 인해 재발 빈도를 감소시키는 방법
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9812730B2 (en) 2011-08-02 2017-11-07 Johnson & Johnson Vision Care, Inc. Biocompatible wire battery
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
US20150307619A1 (en) * 2012-12-13 2015-10-29 The Schepens Eye Research Institute, Inc. Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
ES2884813T3 (es) 2013-03-13 2021-12-13 Buzzard Pharmaceuticals AB Formulaciones de citoquina quimérica para administración ocular
TWI656874B (zh) * 2013-03-13 2019-04-21 日商參天製藥股份有限公司 西羅莫司或其藥學上可容許的鹽之用途
EP3865119A1 (en) 2013-05-02 2021-08-18 Retina Foundation of the Southwest Two-layer ocular implant
US20140343480A1 (en) * 2013-05-19 2014-11-20 Avedro, Inc. Systems, methods, and compositions for cross-linking
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9498122B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
KR102416876B1 (ko) 2014-10-27 2022-07-05 아베드로 인코퍼레이티드 눈의 교차-결합 처리를 위한 시스템 및 방법
WO2016077747A1 (en) 2014-11-13 2016-05-19 Avedro, Inc. Multipass virtually imaged phased array etalon
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016145237A1 (en) * 2015-03-11 2016-09-15 Yu Fu-Shin X Composition and methods to promote wound healing
WO2016172695A1 (en) 2015-04-24 2016-10-27 Avedro, Inc. Systems and methods for photoactivating a photosensitizer applied to an eye
US11324807B2 (en) * 2015-04-28 2022-05-10 Swedish Orphan Biovitrum Ab (Publ) Compositions comprising anakinra
WO2016191342A1 (en) 2015-05-22 2016-12-01 Avedro, Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
EP3324973B1 (en) 2015-07-21 2020-06-03 Avedro, Inc. Treament of an eye with a photosensitizer
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
CN105833234A (zh) * 2016-05-20 2016-08-10 刘传彬 一种纯天然加热外敷治疗筋骨伤痛的中药组合物
JP2019532105A (ja) * 2016-10-14 2019-11-07 アイ．コム メディカル ゲーエムベーハー 角結膜のホメオスタシスを確立、回復及び維持するための方法
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2019176952A1 (en) * 2018-03-13 2019-09-19 Menicon Co., Ltd. Determination System, Computing Device, Determination Method, and Program
WO2019202017A1 (en) 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN108707195B (zh) * 2018-05-31 2019-03-15 苏州大学 翘嘴鳜IFN-α3基因、重组蛋白、制备方法及应用
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
JP2022500461A (ja) * 2018-09-22 2022-01-04 ノバリック ゲーエムベーハー 眼表面の損傷および乾燥の症状の治療のための眼科用組成物
WO2020157570A1 (en) 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
CN110437043A (zh) * 2019-08-24 2019-11-12 黄泳华 由白藜芦醇与前列腺素类似物剂构成的共晶及其在制备抗肿瘤药物中的用途
US20210308154A1 (en) 2020-03-24 2021-10-07 Hovione Scientia Limited Methods and Compositions for Treating Meibomian Gland Dysfunction
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
DK0502956T3 (da) * 1989-11-29 1997-10-20 Amgen Boulder Inc Fremstilling af en rekombinant human interleukin-1-inhibitor.
AU674292B2 (en) * 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5895812A (en) * 1995-05-01 1999-04-20 The University Of Virginia Alumni Patent Foundation Diagnostic for Sjogren's syndrome
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6416753B1 (en) * 1996-03-15 2002-07-09 The General Hospital Corporation Method for modulating apoptosis
US6974682B1 (en) * 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
EP0944395A1 (en) * 1996-11-19 1999-09-29 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
ATE406176T1 (de) * 1996-12-06 2008-09-15 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ATE418989T1 (de) 1998-05-08 2009-01-15 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur behandlung von okularer rosacea
US6432934B1 (en) 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20060262813A1 (en) 1998-12-18 2006-11-23 Digital Networks North America, Inc. Multi-channel video pump
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP3363832B2 (ja) * 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
JP2002154985A (ja) 2000-01-31 2002-05-28 Santen Pharmaceut Co Ltd 眼疾患治療剤
US20010041792A1 (en) * 2000-02-03 2001-11-15 Donda Russell S. Extraction of growth factors from tissue
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20020131954A1 (en) * 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
WO2003090255A2 (en) * 2002-04-18 2003-10-30 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050033694A1 (en) * 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US20050023872A1 (en) * 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) * 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
TR201816556T4 (tr) 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2006091546A2 (en) * 2005-02-22 2006-08-31 The Johns Hopkins School Of Medicine Use of amniotic fluid (af) in treating ocular disease and injury
PT1864666E (pt) * 2005-03-31 2012-09-06 Santen Pharmaceutical Co Ltd Agente protector para célula neuronal retiniana contendo derivado de prostaglandina f2 alfa como ingrediente activo
RU2392938C2 (ru) * 2005-04-13 2010-06-27 Убе Индастриз, Лтд Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола
WO2006119292A2 (en) * 2005-04-29 2006-11-09 Henkin, Robert Methods for detection of biological substances
AU2006304778B2 (en) * 2005-10-21 2011-04-28 Amgen Inc. Methods of decreasing vascular calcification using IL-1 inhibitors
WO2007056812A1 (en) * 2005-11-16 2007-05-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EP2021026A1 (en) 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
CN101489569A (zh) 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
US7758190B2 (en) * 2007-06-20 2010-07-20 Tearscience, Inc. Tear film measurement
JP5894364B2 (ja) * 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders

Also Published As

Publication number Publication date
AU2008289552A1 (en) 2009-02-26
JP2011516400A (ja) 2011-05-26
AU2008289552B2 (en) 2014-10-09
EP2187900A2 (en) 2010-05-26
WO2009025763A3 (en) 2009-04-23
EP2187900A4 (en) 2011-08-17
US20130273065A1 (en) 2013-10-17
WO2009025763A2 (en) 2009-02-26
EP2187900B1 (en) 2016-11-09
JP2016065089A (ja) 2016-04-28
US20100203103A1 (en) 2010-08-12
US10105441B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
JP5894364B2 (ja) 眼および付属器組織の炎症を処置するための治療組成物
JP2011516400A5 (enExample)
Colligris et al. Recent developments on dry eye disease treatment compounds
US10940179B2 (en) Therapeutic compositions for the treatment of dry eye disease
EP2242504B1 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
AU2010203425B2 (en) Therapeutic compositions for treatment of corneal disorders
Bian et al. Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
Skaat et al. Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma
Sadrai et al. Effect of topical azithromycin on corneal innate immune responses
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2640986C (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US11306140B2 (en) Therapeutics for ocular immunoinflammatory diseases
Mautino et al. Side effects of drugs used in ocular treatment
US20220288028A1 (en) A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140312

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140428

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150403

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160226

R150 Certificate of patent or registration of utility model

Ref document number: 5894364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250